Is Nike Stock a Buy, Hold, or Sell? A Comprehensive Analysis

PUBLISHED Apr 26, 2025, 3:10:11 PM        SHARE

img
imgjp_dividends on YouTube

Nike Inc. (NYSE: NKE) has been a giant in the global footwear and apparel industry for decades, but its recent stock performance has raised eyebrows. With a rough start to the year and a significant decline over the past five years, many investors are asking: Is Nike a buy, hold, or sell? Let’s dive into an in-depth analysis, covering Nike's business model, financial health, dividend performance, and valuation.

What Does Nike Do and How Do They Make Money?

Nike is a global powerhouse in designing, developing, marketing, and selling athletic footwear, apparel, equipment, accessories, and services. Although primarily created for athletic purposes, its products are also widely used for casual and leisure activities. Footwear remains the company's largest revenue driver, accounting for the bulk of sales.

This iconic brand’s strong market presence is undeniable. From running shoes to casual sneakers, Nike remains a favorite worldwide—evident in its consistent customer loyalty and widespread visibility.

Nike’s Financial Health: A Mixed Bag

Revenue Trends

Nike's revenue has shown a strong long-term upward trend, growing from $18 billion in 2009 to $51 billion in trailing twelve months by early 2024. However, the past year has been challenging, with revenue slipping from $51 billion to $47 billion—a 7.8% decline. While this setback raises concerns, the three-year trend suggests potential for stabilization and recovery.

Net Income Challenges

Nike’s net income tells a slightly more worrying story. After peaking at $6 billion in 2021, net income has since declined to $4.5 billion—a steep 25% drop. This trend highlights increasing expenses and the need for tighter cost management. While the long-term net income trajectory remains positive, recent declines warrant caution.

Free Cash Flow: A Bright Spot

One standout metric is Nike’s free cash flow (FCF), which has grown consistently over the years. From $2.4 billion in 2013 to a record-breaking year in 2024, the trend is clearly upward. This metric is critical for evaluating a company’s ability to invest in growth, pay dividends, and weather economic challenges, and Nike performs strongly in this area.

Key Financial Metrics

Nike’s valuation and profitability metrics reveal its potential and current market standing:

  • P/E Ratio: At 17, Nike’s price-to-earnings ratio is attractive compared to industry norms, where P/E ratios often exceed 20.
  • Net Profit Margin: At 9.4%, Nike outperforms the average industry margin of 4–5%, demonstrating strong profitability.
  • ROA and ROE: Nike’s Return on Assets (8.2%) and Return on Equity (31.9%) are both solid, surpassing typical benchmarks of 5% and 15%, respectively.

Dividend Analysis

Nike’s dividend performance has significantly improved as its stock price has declined. Key highlights include:

  • Dividend Yield: Currently at 2.92%, up from prior lower levels due to the falling stock price.
  • Five-Year Dividend Growth Rate: 10.6%, reflecting Nike’s commitment to rewarding shareholders.
  • Payout Ratios: The dividend payout ratio is 50.8%, and the cash flow payout ratio is a healthy 39.4%, indicating sustainability and room for growth.

With a 23-year track record of dividend growth, Nike proves its dedication to consistent shareholder returns.

Valuation: Is Nike Undervalued?

Intrinsic value estimates suggest Nike’s stock is significantly undervalued. A DCF (Discounted Cash Flow) model places the intrinsic value at $130 per share, while Simply Wall Street estimates it at $109. With the stock trading at approximately $53.55, this implies potential upside of over 123%.

Despite the challenges, Nike’s free cash flow stability, brand strength, and long-term growth potential make it a compelling case for value investors.

Conclusion: A High-Risk, High-Reward Play

Nike’s current price levels—comparable to its 2015 stock prices—make it an intriguing turnaround story. While the free cash flow and brand strength remain solid, the revenue and net income declines pose significant risks. Investors confident in Nike's ability to reverse these trends may find this an opportune time to buy. However, the investment carries high risks, and cautious optimism is advised.

As always, thorough due diligence and consideration of individual risk tolerance are essential. What are your thoughts on Nike stock? Share your opinions in the comments below!

https://youtu.be/I6E1CBlc58s?si=sfXQ7OZZ2Zxb8XeG



Sound investments
don't happen alone

Find your crew, build teams, compete in VS MODE, and identify investment trends in our evergrowing investment ecosystem. You aren't on an island anymore, and our community is here to help you make informed decisions in a complex world.

More Reads
Unilever Stock: Buy, Hold, or Sell?
Image

In today's analysis, we're diving deep into Unilever stock to determine whether it's a buy, a hold, or a sell. This overview will cover several key aspects: what Unilever does, its financial performance, dividend analysis, and valuation.

Are monthly dividends worth it?
Image

Dividend investing is a tried-and-true method for generating passive income by investing in companies that share a portion of their profits with shareholders. These dividends are typically distributed on a regular schedule, making them an attractive option for investors looking for predictable returns.

Is Home Depot Stock a Buy, Hold, or Sell? A Comprehensive Analysis
Image

Today, we're diving deep into Home Depot (HD), the go-to retailer for all things home improvement. We'll analyze whether it's a buy, hold, or sell by examining its business model, financials, dividend performance, and valuation.

Are dividend stocks good for passive income?
Image

Dividend stocks are shares of companies that regularly distribute a portion of their earnings to shareholders in the form of dividends. These payouts often serve as an incentive for investors seeking steady income, making dividend stocks a popular choice for passive income strategies.

The Big Flaw of the P/E Ratio (and How to Fix it)
Image

The stock market's current turbulence has left retail investors searching for reliable indicators to guide them back into equities. Among these indicators, the price-to-earnings (P/E) ratio stands out as one of the most commonly discussed metrics, having been a cornerstone of investing for nearly a century.

Lululemon: Undervalued Opportunity or Value Trap?
Image

Ticker symbol LULU has seen a significant drop of over 20%, leaving investors questioning whether Lululemon represents an undervalued opportunity or a value trap.

The Trade Desk (Ticker: TTD): A Look at Explosive Growth and Unique Offerings
Image

Ticker symbol TTD has skyrocketed over 80% in the past year, making The Trade Desk a standout performer in the stock market. With a remarkable 102% year-over-year net income growth and consistent margin expansion, this digital advertising powerhouse is revolutionizing the way businesses approach marketing campaigns.

Novo Nordisk: A Stock Under Pressure, but Is It a Value Opportunity?
Image

Novo Nordisk, the Danish pharmaceutical giant, has experienced a significant price dip, falling over 40% from its all-time highs in June 2024. This decline stems from several challenges, including the entrance of competitors offering weight-loss drugs, less successful clinical trial results than anticipated, and heightened uncertainty due to new U.S. political administration policies and potential tariffs on foreign pharmaceutical companies.

ASML Stock: Balancing Risk and Reward Amid Cyclicality
Image

Good day, fellow investors! ASML Holding (ASML) has faced a challenging stretch in recent months, with the stock down 42% over the last 10 months. Tariff concerns and market uncertainty have weighed heavily on its price.

BHP Stock: Long-Term Potential Amid Cyclical Downturns
Image

Good day, fellow investors! BHP Group (BHP) has faced a challenging period, with its stock down 30% over the last two years. Yet, the fundamentals remain strong—cash flows are healthy, dividends are consistent, and the market capitalization stands at a notable $126 billion.

STAG Industrial Stock: Is It Time to Invest?
Image

The stock market’s recent volatility has impacted all sectors, including Real Estate Investment Trusts (REITs). Among those facing a downturn is STAG Industrial (STAG), with its stock down approximately 25% from its 52-week high and nearing its 52-week low.

ARCC Stock: A Dividend Investor’s Dream?
Image

If you’re a dividend enthusiast, Ares Capital Corporation (ARCC) might already be on your radar. Known for its stellar dividend yields, ARCC has recently taken a hit, with its stock falling 15-20% from its year-to-date high.

LTC Stock Analysis: Is This Real Estate Investment Trust (REIT) Worth Your Attention?
Image

The stock market has been tumultuous lately, making it crucial for investors to seek out promising opportunities. One such contender is LTC Properties, Inc. (NYSE: LTC), a REIT specializing in healthcare facilities such as assisted living and skilled nursing properties.

Eli Lilly Stock: Analyzing its Valuation and Future Potential
Image

Eli Lilly (NYSE: LLY), a pharmaceutical giant with a market cap of $658 billion, has achieved impressive growth in recent years, primarily driven by its diabetes drugs, Mounjaro and Trulicity. But with a current stock price of $732, is Eli Lilly overvalued, or does it present an opportunity for long-term investors? Let’s break down the numbers and evaluate its valuation.

Pfizer Stock: A Deep Dive into Valuation and Investment Potential
Image

When it comes to the pharmaceutical industry, Pfizer stands tall as a legacy company with a rich history of innovation. However, its recent financial performance and stock price movements have left investors questioning its valuation. At a market cap of $124 billion and a trading price of $22 per share, is Pfizer undervalued, or does the dip signal deeper challenges?

Is Sanofi Stock Trading at an Undervalued Price? Here's What You Need to Know
Image

Investing in pharmaceutical stocks often means betting on innovation and consistent cash flow. With a strong market presence and a robust portfolio, Sanofi is no exception. But is it currently undervalued or an opportunity waiting to be seized? In this detailed analysis, we’ll dissect Sanofi’s financial statements and ratios to determine whether this large-cap stock should be on your radar.

Unlocking the Value of Boyd Gaming Stock: Is It a Buy or Sell?
Image

In the ever-evolving world of investing, evaluating stocks to determine their worth and potential can be as thrilling as a game of chance at a casino. Boyd Gaming Corporation (NYSE: BYD), a prominent player in the gaming and hospitality industry, is no exception.

Why Miners Are Losing Faith, But MicroStrategy Holds Strong: A Deep Dive into CleanSpark, Iron, and MARA
Image

The cryptocurrency landscape is no stranger to volatility, but recent developments in the Bitcoin mining sector have sparked heated debates among investors. With miners like CleanSpark making controversial strategic shifts and MicroStrategy steadfastly holding its Bitcoin, the industry is at a pivotal crossroads.

Why HIMS is a Recession-Proof Investment: Essential, Affordable, and Growing
Image

When economic uncertainties arise, investors tend to react by selling stocks across the board. Yet, there are companies that not only weather recessions but thrive during them. **HIMS & HERS Health Inc.**, a telehealth pioneer, stands out as one such example. Here's why HIMS remains a compelling investment, even in the face of economic downturns.

Pfizer Stock: Analyzing Opportunities Amid a 63% Decline
Image

Pfizer Inc. (NYSE: PFE) has experienced a dramatic decline in its stock price, plummeting 63% from its all-time high. With the dividend yield now approaching 8%, many investors are evaluating whether this is a lucrative buying opportunity or a potential trap.

Resources for Publishers
Resources for New Investors
Boosted with BossCoin
Top Investors
user_profile
Tom Hamilton
user_profile
Wise Intelligent
user_profile
Mark Robertson
user_profile
Kevin Matthews II
user_profile
Akeiva Ellis
user_profile
Brendan Dale
user_profile
Kenneth Chavis IV
user_profile
Sharita Humphrey